Reference Detail

Ref Type

PMID

Authors

Toan Pham, Shienny Sampurno, Lloyd Pereira, Sara Roth, Vignesh Narasimhan, Sandra Carpinteri, Alexander Heriot, Jayesh Desai, Robert G.Ramsay

Title

Cancer Vaccine Targeting MYB in Colorectal Cancer: From Pre-Clinical Model to Clinical Trial

Journal	Vol	Issue	Date	Pages	Journal Short Title
Gastroenterology			May 2018

URL

Abstract Text

Gastroenterology Volume 154, Issue 6, Supplement 1, May 2018, Pages S-1269

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Treatment Approach

Gene Name	Source	Synonyms	Protein Domains	Gene Description	Gene Role

Therapy Name	Drugs	Efficacy Evidence	Clinical Trials
TetMYB	TetMYB	1	0

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
TetMYB		MYB vaccine		TetMYB is a DNA vaccine comprised of a modified full-length MYB coding region linked to tetanus peptides, which results in enhanced immune response to MYB expressing tumor cells (Gastroenterology, Volume 154, Issue 6, Supplement 1, May 2018, Pages S-1269, PMID: 25671128, PMID: 31650066).

Gene	Variant	Impact	Protein Effect	Variant Description	Associated with drug Resistance

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
APC mutant	colon adenoma	predicted - sensitive	TetMYB	Preclinical	Actionable	In a preclinical study, TetMYB treatment resulted in improved median survival compared to control (356 vs 183 days) in APC-driven mouse models of colon adenoma (Gastroenterology, Volume 154, Issue 6, Supplement 1, May 2018, Pages S-1269).	detail...